Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297410 | 0.86 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL29322818 | 0.82 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL10308899 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL23179776 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL23179778 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL31265606 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL31265610 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL7297402 | 0.76 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL22625575 | 0.76 | ADRA2C (0.41) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL21200125 | 0.76 | ADRA2C (0.41) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | SLC6A2 873/4885SLC6A3 959/4885SLC6A4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.